

Paolo Bossi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7245433/publications.pdf>

Version: 2024-02-01

290
papers

9,745
citations

43973

48
h-index

53109

85
g-index

297
all docs

297
docs citations

297
times ranked

10421
citing authors

#	ARTICLE	IF	CITATIONS
1	International Multicenter Study of Clinical Outcomes of Sinonasal Melanoma Shows Survival Benefit for Patients Treated with Immune Checkpoint Inhibitors and Potential Improvements to the Current TNM Staging System. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2023, 84, 307-319.	0.4	10
2	A European survey on the practice of nutritional interventions in head&neck cancer patients undergoing curative treatment with radio(chemo)therapy. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, 279, 1499-1508.	0.8	3
3	Regional disease in head and neck cutaneous squamous cell carcinoma: the role of primary tumor characteristics and number of nodal metastases. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, 279, 1573-1584.	0.8	6
4	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 865-874.	2.0	11
5	The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts. <i>Cancers</i> , 2022, 14, 377.	1.7	17
6	A nationwide survey among emergency physicians and oncologists to improve the management of immune checkpoint inhibitors toxicity. <i>Supportive Care in Cancer</i> , 2022, , 1.	1.0	1
7	Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group. <i>Frontiers in Oncology</i> , 2022, 12, 730785.	1.3	1
8	Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. <i>European Journal of Cancer</i> , 2022, 162, 221-236.	1.3	22
9	Biological properties of hypoxia-related gene expression models/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials. <i>Oral Oncology</i> , 2022, 126, 105756.	0.8	1
10	Baseline prognostic factors affecting survival in recurrent and/or metastatic salivary gland adenoid cystic carcinoma. <i>Oral Oncology</i> , 2022, 126, 105764.	0.8	8
11	Refining Tumor Treatment in Sinonasal Cancer Using Delta Radiomics of Multi-Parametric MRI after the First Cycle of Induction Chemotherapy. <i>Journal of Imaging</i> , 2022, 8, 46.	1.7	6
12	Multicenter Analysis of Clinical Outcomes of Sinonasal Mucosal Melanoma. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2022, 83, .	0.4	0
13	Different inflammatory blood markers correlate with specific outcomes in incident HPV-negative head and neck squamous cell carcinoma: a retrospective cohort study. <i>BMC Cancer</i> , 2022, 22, 243.	1.1	3
14	The Burning Question: Prophylactic Gabapentin for Mucositis-Related Pain in Patients Undergoing Chemoradiation Therapy for Head and Neck Cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 938-941.	0.4	1
15	Treatment de&escalation for <scp>HPV</scp>+ oropharyngeal cancer: A systematic review and meta&analysis. <i>Head and Neck</i> , 2022, 44, 1255-1266.	0.9	16
16	Unmet Needs and Perspectives in Oral Cancer Prevention. <i>Cancers</i> , 2022, 14, 1815.	1.7	14
17	Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions. <i>Cells</i> , 2022, 11, 32.	1.8	6
18	Estimating survival after salvage surgery for recurrent salivary gland cancers: Systematic review. <i>Head and Neck</i> , 2022, 44, 1961-1975.	0.9	3

#	ARTICLE	IF	CITATIONS
19	Clinical and Histological Prognostic Factors of Recurrence and Malignant Transformation in a Large Series of Oral Potentially Malignant Disorders. <i>Frontiers in Oncology</i> , 2022, 12, 886404.	1.3	1
20	Confounding factors in the assessment of oral mucositis in head and neck cancer. <i>Supportive Care in Cancer</i> , 2022, 30, 8455-8463.	1.0	3
21	Salvage surgery in recurrent sinonasal cancers: Proposal for a prognostic model based on clinicopathologic and treatment-related parameters. <i>Head and Neck</i> , 2022, 44, 1857-1870.	0.9	7
22	New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Vaccines</i> , 2022, 10, 885.	2.1	2
23	Does Reorganization of Clinicopathological Information Improve Prognostic Stratification and Prediction of Chemoradiosensitivity in Sinonasal Carcinomas? A Retrospective Study on 145 Patients. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	2
24	Immunotherapy followed by cetuximab in locally advanced/metastatic (LA/M) cutaneous squamous cell carcinomas (cSCC): The I-TACKLE trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9520-9520.	0.8	5
25	Cytotoxic effects of targeted agent alone or with chemotherapy in the treatment of adenoid cystic carcinoma: a preclinical study. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
26	Clinical and pathological prognostic factors in Merkel cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21574-e21574.	0.8	0
27	Efficacy of a nurse monitoring service at preventing disease- or therapy-related symptoms in patients receiving targeted therapy or immunotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 12118-12118.	0.8	0
28	The MUSESâ—: a prognostic study on 1360 patients with sinonasal cancer undergoing endoscopic surgery-based treatment. <i>European Journal of Cancer</i> , 2022, 171, 161-182.	1.3	18
29	Immune-related gene expression signature in patients with recurrent/metastatic head and neck cancer treated with immunotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6051-6051.	0.8	0
30	MASCC/ISOO clinical practice guidelines for the management of mucositis: sub-analysis of current interventions for the management of oral mucositis in pediatric cancer patients. <i>Supportive Care in Cancer</i> , 2021, 29, 3539-3562.	1.0	33
31	Defining the needs of patients with recurrent and/or metastatic head and neck cancer: An expert opinion. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103200.	2.0	9
32	Psychometric properties of the Italian version of the Speech Handicap Index. <i>Disability and Rehabilitation</i> , 2021, 43, 1307-1312.	0.9	3
33	Optimal Supportive Measures during Primary Treatment. , 2021, , 221-230.		0
34	The efficacy of immunonutrition in improving tolerance to chemoradiotherapy in patients with head and neck cancer, receiving nutritional counseling: study protocol of a randomized, open-label, parallel group, bicentric pilot study. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110258.	1.4	5
35	Peripherally or centrally inserted central catheters: what is the best vascular access device for cancer patients?. <i>Supportive Care in Cancer</i> , 2021, 29, 2803-2806.	1.0	3
36	Prognostic Significance of CD4+ and CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. <i>Cancers</i> , 2021, 13, 781.	1.7	62

#	ARTICLE	IF	CITATIONS
37	Sinonasal cancer encroaching the orbit: Ablation or preservation?. <i>Oral Oncology</i> , 2021, 114, 105185.	0.8	19
38	The role of benzydamine in prevention and treatment of chemoradiotherapy-induced mucositis. <i>Supportive Care in Cancer</i> , 2021, 29, 5701-5709.	1.0	23
39	The appropriate use of circulating EBV-DNA in nasopharyngeal carcinoma: Comprehensive clinical practice guidelines evaluation. <i>Oral Oncology</i> , 2021, 114, 105128.	0.8	11
40	Sinonasal cancers treatments: state of the art. <i>Current Opinion in Oncology</i> , 2021, 33, 196-205.	1.1	17
41	Immunonutrition in head and neck cancer patients undergoing chemoradiotherapy: an alternative approach for overcoming potential bias. <i>American Journal of Clinical Nutrition</i> , 2021, 113, 1053-1054.	2.2	2
42	M. D. Anderson symptom inventory head neck (MDASI-HN) questionnaire: Italian language psychometric validation in head and neck cancer patients treated with radiotherapy±systemic therapy â€œ A study of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). <i>Oral Oncology</i> , 2021, 115, 105189.	0.8	6
43	Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma. <i>Oral Oncology</i> , 2021, 115, 105213.	0.8	33
44	Immunotherapy for the prevention of high-risk oral disorders malignant transformation: the IMPEDE trial. <i>BMC Cancer</i> , 2021, 21, 561.	1.1	5
45	Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies. <i>Cancers</i> , 2021, 13, 2371.	1.7	35
46	Gene Expression Profiling of Olfactory Neuroblastoma Helps Identify Prognostic Pathways and Define Potentially Therapeutic Targets. <i>Cancers</i> , 2021, 13, 2527.	1.7	17
47	Prognostic role of pre-treatment magnetic resonance imaging (MRI)-based radiomic analysis in effectively cured head and neck squamous cell carcinoma (HNSCC) patients. <i>Acta Oncologica</i> , 2021, 60, 1192-1200.	0.8	13
48	Brain metastasis in head and neck squamous cell carcinoma after immune check point inhibitors treatment. <i>Oral Oncology</i> , 2021, 116, 105138.	0.8	1
49	Malignant salivary gland tumours in families with breast cancer susceptibility. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 221-226.	1.4	0
50	Survival and toxicity of weekly cisplatin chemoradiotherapy versus three-weekly cisplatin chemoradiotherapy for head and neck cancer: A systematic review and meta-analysis endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103345.	2.0	9
51	What to Do and What Not to Do in the Management of Cancer Pain: A Physician Survey and Expert Recommendations. <i>Cancer Management and Research</i> , 2021, Volume 13, 5203-5210.	0.9	2
52	Sinonasal Squamous Cell Carcinoma, a Narrative Reappraisal of the Current Evidence. <i>Cancers</i> , 2021, 13, 2835.	1.7	23
53	The Spectrum of Malnutrition/Cachexia/Sarcopenia in Oncology According to Different Cancer Types and Settings: A Narrative Review. <i>Nutrients</i> , 2021, 13, 1980.	1.7	135
54	Prognostic value of H&E index in patients surgically treated for squamous cell carcinoma of the larynx. <i>Laryngoscope Investigative Otolaryngology</i> , 2021, 6, 729-737.	0.6	6

#	ARTICLE	IF	CITATIONS
55	A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Efficacy of Aqualief™ Mucoadhesive Tablets in Head and Neck Cancer Patients Who Developed Radiation-Induced Xerostomia. <i>Cancers</i> , 2021, 13, 3456.	1.7	3
56	Overview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies. <i>Cancers</i> , 2021, 13, 3696.	1.7	30
57	Patient selection for immunotherapy in head and neck cancer. <i>Lancet Oncology</i> , The, 2021, 22, e290.	5.1	2
58	Not all hematopoietic growth factors are created equal: should we gain information for their use with immunotherapy?. , 2021, 9, e003154.		0
59	The Association between Vitamin D and Gut Microbiota: A Systematic Review of Human Studies. <i>Nutrients</i> , 2021, 13, 3378.	1.7	36
60	Vitamin D Supplementation and Cancer Mortality: Narrative Review of Observational Studies and Clinical Trials. <i>Nutrients</i> , 2021, 13, 3285.	1.7	23
61	Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 4061-4068.	0.8	24
62	Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. <i>European Journal of Cancer</i> , 2021, 157, 250-258.	1.3	52
63	The impact of the COVID-19 outbreak on supportive care for oral mucositis: current concepts and practice. <i>Supportive Care in Cancer</i> , 2021, 29, 2255-2258.	1.0	5
64	Genome-wide study of salivary miRNAs identifies miR-423-5p as promising diagnostic and prognostic biomarker in oral squamous cell carcinoma. <i>Theranostics</i> , 2021, 11, 2987-2999.	4.6	37
65	New and Promising Targeted Therapies in First and Second-Line Settings. , 2021, , 277-296.		0
66	Oral potentially malignant disorders: new insights for future treatment. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2021, 29, 138-142.	0.8	5
67	Accurate Triage of Oncological Patients for Safely Continuing Cancer Therapy During the SARS-CoV-2 Pandemic. <i>Frontiers in Oncology</i> , 2021, 11, 707346.	1.3	1
68	Treatment of Cutaneous Squamous Cell Carcinoma with Immune Checkpoint Inhibitors in Special Populations. <i>Dermatology Practical and Conceptual</i> , 2021, 11, e2021170S.	0.5	1
69	Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort. <i>European Journal of Cancer</i> , 2021, 159, 194-204.	1.3	13
70	Immunotherapy for Cutaneous Squamous Cell Carcinoma: Results and Perspectives. <i>Frontiers in Oncology</i> , 2021, 11, 727027.	1.3	15
71	Locally advanced epithelial sinonasal tumors: The impact of multimodal approach. <i>Laryngoscope</i> , 2020, 130, 857-865.	1.1	25
72	Prognostic role of primary tumor, nodal neck, and retropharyngeal GTVs for unresectable sinonasal cancers treated with IMRT and chemotherapy. <i>Tumori</i> , 2020, 106, 39-46.	0.6	6

#	ARTICLE	IF	CITATIONS
73	Randomized Phase 2 Trial of a Novel Clonidine Mucoadhesive Buccal Tablet for the Amelioration of Oral Mucositis in Patients Treated With Concomitant Chemoradiation Therapy for Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 320-328.	0.4	15
74	Is pain part of a systemic syndrome in head and neck cancer?. <i>Supportive Care in Cancer</i> , 2020, 28, 451-459.	1.0	16
75	Management of sinonasal adenocarcinomas with anterior skull base extension. <i>Journal of Neuro-Oncology</i> , 2020, 150, 405-417.	1.4	14
76	Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2020, 28, 2449-2456.	1.0	60
77	Role of IMRT/VMAT-Based Dose and Volume Parameters in Predicting 5-Year Local Control and Survival in Nasopharyngeal Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 518110.	1.3	9
78	Baseline MRI-Radiomics Can Predict Overall Survival in Non-Endemic EBV-Related Nasopharyngeal Carcinoma Patients. <i>Cancers</i> , 2020, 12, 2958.	1.7	29
79	Value and Quality of Care in Head and Neck Oncology. <i>Current Oncology Reports</i> , 2020, 22, 92.	1.8	15
80	Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in the era of COVID-19: stop or go? Data from five Italian referral cancer centers. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097700.	1.4	6
81	Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions. <i>Cells</i> , 2020, 9, 1828.	1.8	13
82	A randomized, double-blind, placebo controlled, phase II study to evaluate the efficacy of ginseng in reducing fatigue in patients treated for head and neck cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2479-2487.	1.2	12
83	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i> , 2020, 126, 4423-4431.	2.0	540
84	The Evolving Role of Systemic Therapy in the Primary Treatment of Sinonasal Cancer. <i>Advances in Oto-Rhino-Laryngology</i> , 2020, 84, 78-86.	1.6	3
85	Pretreatment DWI with Histogram Analysis of the ADC in Predicting the Outcome of Advanced Oropharyngeal Cancer with Known Human Papillomavirus Status Treated with Chemoradiation. <i>American Journal of Neuroradiology</i> , 2020, 41, 1473-1479.	1.2	10
86	The 8th TNM classification for oral squamous cell carcinoma: What is gained, what is lost, and what is missing. <i>Oral Oncology</i> , 2020, 111, 104937.	0.8	20
87	A monocentric, open-label randomized standard-of-care controlled study of XONRIDÂ®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients. <i>Radiation Oncology</i> , 2020, 15, 193.	1.2	9
88	The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures. <i>Frontiers in Oncology</i> , 2020, 10, 1574.	1.3	5
89	Assessing Preferences in Patients with Head and Neck Squamous Cell Carcinoma: Phase I and II of Questionnaire Development. <i>Cancers</i> , 2020, 12, 3577.	1.7	4
90	Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study. <i>Future Oncology</i> , 2020, 16, 1091-1100.	1.1	3

#	ARTICLE	IF	CITATIONS
91	Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives. <i>Supportive Care in Cancer</i> , 2020, 28, 4589-4612.	1.0	156
92	Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders. <i>Oncologist</i> , 2020, 25, e946-e954.	1.9	3
93	Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action. <i>Supportive Care in Cancer</i> , 2020, 28, 5059-5073.	1.0	40
94	Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands. <i>European Journal of Cancer</i> , 2020, 136, 35-42.	1.3	27
95	Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life. <i>Cancer</i> , 2020, 126, 1888-1894.	2.0	54
96	A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 187-204.	1.0	5
97	Relevance of apparent diffusion coefficient features for a radiomics-based prediction of response to induction chemotherapy in sinonasal cancer. <i>NMR in Biomedicine</i> , 2020, , e4265.	1.6	15
98	Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2020, 28, 2485-2498.	1.0	42
99	Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2020, 28, 2473-2484.	1.0	46
100	Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines – part 2: honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents. <i>Supportive Care in Cancer</i> , 2020, 28, 2457-2472.	1.0	54
101	Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 922.	1.7	12
102	Precision medicine in rare tumors and the need for multicenter trials and international collaboratives: Sinonasal cancer as paradigm. <i>Oral Oncology</i> , 2020, 109, 104737.	0.8	6
103	Malignant tumors of the maxillary sinus: Prognostic impact of neurovascular invasion in a series of 138 patients. <i>Oral Oncology</i> , 2020, 106, 104672.	0.8	17
104	Future Perspectives in the Management of Tumors of the Anterior Skull Base. <i>Advances in Oto-Rhino-Laryngology</i> , 2020, 84, 246-250.	1.6	3
105	Prognostic role of pre-treatment magnetic resonance imaging (MRI) radiomic analysis in patients with squamous cell carcinoma of the head and neck (SCCHN). <i>Journal of Clinical Oncology</i> , 2020, 38, 6553-6553.	0.8	0
106	Treatment Options for Recurrent Anterior Skull Base Tumors. <i>Advances in Oto-Rhino-Laryngology</i> , 2020, 84, 231-245.	1.6	2
107	Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer. <i>Dysphagia</i> , 2019, 34, 52-62.	1.0	9
108	Could the extreme conformality achieved with proton therapy in paranasal sinuses cancers accidentally results in a high rate of leptomeningeal progression?. <i>Head and Neck</i> , 2019, 41, 3733-3735.	0.9	2

#	ARTICLE	IF	CITATIONS
109	Development of the MASCC/ISOO clinical practice guidelines for mucositis: an overview of the methods. <i>Supportive Care in Cancer</i> , 2019, 27, 3933-3948.	1.0	32
110	Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Follow-up. <i>Otolaryngology - Head and Neck Surgery</i> , 2019, 161, 635-642.	1.1	26
111	Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2019, 27, 3949-3967.	1.0	127
112	Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2019, 27, 3969-3983.	1.0	213
113	The pathogenesis of mucositis: updated perspectives and emerging targets. <i>Supportive Care in Cancer</i> , 2019, 27, 4023-4033.	1.0	106
114	Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelinesâ€”part 1: vitamins, minerals, and nutritional supplements. <i>Supportive Care in Cancer</i> , 2019, 27, 3997-4010.	1.0	54
115	Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2019, 27, 3985-3995.	1.0	76
116	Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2019, 27, 4011-4022.	1.0	51
117	Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2019, 11, 1057.	1.7	25
118	Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract. <i>Head and Neck</i> , 2019, 41, 3670-3676.	0.9	29
119	Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck Cancer. <i>Clinical Therapeutics</i> , 2019, 41, 2517-2528.e28.	1.1	2
120	Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , 2019, 123, 138-145.	1.3	13
121	A pilot study of a smartphone-based monitoring intervention on head and neck cancer patients undergoing concurrent chemo-radiotherapy. <i>International Journal of Medical Informatics</i> , 2019, 129, 404-412.	1.6	35
122	Difficulties in conducting pure academic research, obstacles in data collection and quality of informations: The example of the INTERCEPTOR study. <i>Oral Oncology</i> , 2019, 97, 99-104.	0.8	3
123	Postoperative radiotherapy (PORT) for early oral cavity cancer (pT1-2,N0-1): A review. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 67-75.	2.0	21
124	Quality Assessment in Supportive Care in Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 926.	1.3	8
125	Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer. <i>Head and Neck</i> , 2019, 41, 908-914.	0.9	3
126	Prognostic Nomograms in Oral Squamous Cell Carcinoma: The Negative Impact of Low Neutrophil to Lymphocyte Ratio. <i>Frontiers in Oncology</i> , 2019, 9, 339.	1.3	32

#	ARTICLE	IF	CITATIONS
127	May we rely on induction chemotherapy again as a biological selection of radiosensitive head and neck cancer?. <i>Oral Oncology</i> , 2019, 94, 121-122.	0.8	1
128	PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents. <i>Oncology</i> , 2019, 97, 112-118.	0.9	1
129	Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting. <i>European Journal of Cancer</i> , 2019, 115, 4-12.	1.3	18
130	Identification of potentially druggable molecular alterations in skin adnexal malignancies. <i>Journal of Dermatology</i> , 2019, 46, 507-514.	0.6	9
131	Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 435-443.	1.9	8
132	Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 137, 84-91.	2.0	55
133	The point of pain in head and neck cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 51-59.	2.0	30
134	A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes. <i>Oral Oncology</i> , 2019, 90, 94-101.	0.8	12
135	The role of age in treatment-related adverse events in patients with head and neck cancer: A systematic review. <i>Head and Neck</i> , 2019, 41, 2410-2429.	0.9	24
136	Prevalence of Fatigue in Head and Neck Cancer Survivors. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2019, 128, 413-419.	0.6	30
137	Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1909-1915.	1.9	21
138	Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy. <i>Future Oncology</i> , 2019, 15, 2543-2553.	1.1	10
139	Systemic treatment in elderly head and neck cancer patients: recommendations for clinical practice. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2019, 27, 142-150.	0.8	24
140	Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2019, 41, 1895-1902.	0.9	10
141	Role of pretreatment 18F-FDG PET/CT parameters in predicting outcome of non-endemic EBV DNA-related nasopharyngeal cancer (NPC) patients treated with IMRT and chemotherapy. <i>Radiologia Medica</i> , 2019, 124, 414-421.	4.7	16
142	Hyperprogressive disease (HPD) in head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , 2019, 37, 6029-6029.	0.8	2
143	Clinical prognostic factors in patients with recurrent or metastatic carcinoma of the head and neck treated with immune checkpoints therapies.. <i>Journal of Clinical Oncology</i> , 2019, 37, e17530-e17530.	0.8	3
144	Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment. <i>Drugs in Context</i> , 2019, 8, 1-6.	1.0	7

#	ARTICLE	IF	CITATIONS
145	AUCtox: A new method to evaluate the safety of anticancer drugs in metastatic prostate cancer.. Journal of Clinical Oncology, 2019, 37, 290-290.	0.8	0
146	Retrospective analysis of baseline clinical factors associated to CDDP-nephrotoxicity in locally advanced head and neck cancer (LAHNC) patients.. Journal of Clinical Oncology, 2019, 37, e17537-e17537.	0.8	0
147	Global cancer control: responding to the growing burden, rising costs and inequalities in access. ESMO Open, 2018, 3, e000285.	2.0	169
148	Lenvatinib-induced renal failure: two first-time case reports and review of literature. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 379-385.	1.5	27
149	Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN). Annals of Oncology, 2018, 29, 985-991.	0.6	36
150	Comment on "Human papillomavirus association is the most important predictor for surgically treated patients with oropharyngeal cancer". British Journal of Cancer, 2018, 118, e5-e5.	2.9	1
151	Failure of Further Validation for Survival Nomograms in Oropharyngeal Cancer: Issues and Challenges. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1217-1221.	0.4	9
152	Retreatment with Vismodegib after Progression in Advanced Basal Cell Carcinoma: First-Time Report of a Single-Institution Experience. Targeted Oncology, 2018, 13, 253-256.	1.7	11
153	Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers. Tumori, 2018, 104, 213-220.	0.6	4
154	Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. Cancer Treatment Reviews, 2018, 65, 78-86.	3.4	32
155	The use of fentanyl in pain management in head and neck cancer patients: a narrative review. British Journal of Pain, 2018, 12, 155-162.	0.7	9
156	Impact of treatment expertise on the outcome of patients with head and neck cancer treated within 6 randomized trials. Head and Neck, 2018, 40, 2648-2656.	0.9	7
157	In Reply to Fakhry et al. International Journal of Radiation Oncology Biology Physics, 2018, 102, 670-671.	0.4	1
158	Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients. Oral Oncology, 2018, 86, 266-272.	0.8	26
159	Nutrition in patients with cancer: a new area for medical oncologists? A practising oncologist's interdisciplinary position paper. ESMO Open, 2018, 3, e000345.	2.0	23
160	Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. European Journal of Cancer, 2018, 97, 7-15.	1.3	34
161	Managing older patients with head and neck cancer: The non-surgical curative approach. Journal of Geriatric Oncology, 2018, 9, 411-417.	0.5	9
162	Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Annals of Oncology, 2018, 29, iv126-iv142.	0.6	83

#	ARTICLE	IF	CITATIONS
163	Addressing the quality of life needs of older patients with cancer: a SIOG consensus paper and practical guide. <i>Annals of Oncology</i> , 2018, 29, 1718-1726.	0.6	103
164	The use of intensive radiological assessments in routine surveillance after treatment for head and neck cancer: An economic evaluation. <i>European Journal of Cancer</i> , 2018, 93, 89-98.	1.3	14
165	Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. <i>Oral Oncology</i> , 2018, 82, 144-151.	0.8	13
166	Fatigue, a major still underestimated issue. <i>Current Opinion in Oncology</i> , 2018, 30, 219-225.	1.1	23
167	Phase II study on lenvatinib (LEN) in recurrent and/or metastatic (R/M) adenoid cystic carcinomas (ACC) of the salivary glands (SG) of the upper aerodigestive tract (NCT02860936).. <i>Journal of Clinical Oncology</i> , 2018, 36, 6086-6086.	0.8	7
168	Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?. <i>Oral Oncology</i> , 2017, 66, 58-63.	0.8	90
169	Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. <i>Oral Oncology</i> , 2017, 69, 33-37.	0.8	16
170	Toward Personalized Cancer Care for Elderly Head and Neck Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 965-966.	0.4	5
171	Eliciting Preferences for Clinical Follow-Up in Patients with Head and Neck Cancer Using Best-Worst Scaling. <i>Value in Health</i> , 2017, 20, 799-808.	0.1	15
172	Preemptive treatment with Xonrid [®] , a medical device to reduce radiation induced dermatitis in head and neck cancer patients receiving curative treatment: a pilot study. <i>Supportive Care in Cancer</i> , 2017, 25, 1787-1795.	1.0	12
173	The Case Volume Issue in Head and Neck Oncology. <i>Current Treatment Options in Oncology</i> , 2017, 18, 65.	1.3	5
174	A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2017, 28, 2820-2826.	0.6	66
175	The vicious circle of treatment-induced toxicities in locally advanced head and neck cancer and the impact on treatment intensity. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 116, 82-88.	2.0	9
176	A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin. <i>Annals of Oncology</i> , 2017, 28, 2547-2551.	0.6	47
177	Integrative miRNA-Gene Expression Analysis Enables Refinement of Associated Biology and Prediction of Response to Cetuximab in Head and Neck Squamous Cell Cancer. <i>Genes</i> , 2017, 8, 35.	1.0	27
178	Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?. <i>Disease Markers</i> , 2017, 2017, 1-9.	0.6	4
179	An Environment for Guidelinebased Decision Support Systems for Outpatients Monitoring. <i>Methods of Information in Medicine</i> , 2017, 56, 283-293.	0.7	8
180	Efficacy and safety of single agent pan-HER inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer (sSCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9543-9543.	0.8	5

#	ARTICLE	IF	CITATIONS
181	Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area. <i>Oncotarget</i> , 2017, 8, 47780-47789.	0.8	32
182	RANK expression in EBV positive nasopharyngeal carcinoma metastasis: a ready-to-treat target?. <i>Oncotarget</i> , 2017, 8, 96184-96189.	0.8	4
183	Ambrosio Borsano: un exponente de la escuela de ingenierÃa militar de MilÃn al servicio de la MonarquÃa HispÃnica (1633-1661). <i>Hispania - Revista Espanola De Historia</i> , 2017, 77, 673.	0.2	1
184	Safety of Combination Treatment with Imatinib Mesylate, Carboplatin, and Cetuximab in a Patient with Multiple Cancers: A Case Report. <i>Tumori</i> , 2016, 102, S1-S2.	0.6	1
185	Temporal course and predictive factors of analgesic opioid requirement for chemoradiationâ€induced oral mucositis in oropharyngeal cancer. <i>Head and Neck</i> , 2016, 38, E1521-7.	0.9	25
186	Health careâ€associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy. <i>Head and Neck</i> , 2016, 38, E1009-13.	0.9	6
187	Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. <i>Supportive Care in Cancer</i> , 2016, 24, 4057-4074.	1.0	21
188	Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma. <i>Oral Oncology</i> , 2016, 58, e4-e5.	0.8	3
189	Investigational drugs for head and neck cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 797-810.	1.9	12
190	Searching for Evidence to Support the Use of Ginger in the Prevention of Chemotherapy-Induced Nausea and Vomiting. <i>Journal of Alternative and Complementary Medicine</i> , 2016, 22, 486-488.	2.1	10
191	Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2016, 67, 174-182.	1.3	75
192	The Benefit of a Multidisciplinary Approach to the Patient Treated with (Chemo) Radiation for Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 53.	1.3	15
193	Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 959-966.	0.4	48
194	A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. <i>European Journal of Cancer</i> , 2016, 69, 158-165.	1.3	66
195	Respiratory illness and air pollution from the steel industry: the case of PiquiÃ de Baixo, Brazil (Preliminary report). <i>Multidisciplinary Respiratory Medicine</i> , 2016, 11, 41.	0.6	5
196	Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. <i>Head and Neck</i> , 2016, 38, E2151-8.	0.9	146
197	Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. <i>Clinical Cancer Research</i> , 2016, 22, 3961-3970.	3.2	65
198	Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptorâ€positive salivary gland cancers. <i>Head and Neck</i> , 2016, 38, 724-731.	0.9	104

#	ARTICLE	IF	CITATIONS
199	Paranasal sinus cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 45-61.	2.0	41
200	Pain management in head and neck cancer patients undergoing chemo-radiotherapy: Clinical practical recommendations. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 100-106.	2.0	62
201	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 102, 47-54.	2.0	51
202	Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer?. <i>Oral Oncology</i> , 2016, 54, 54-57.	0.8	46
203	Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements.. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 147-166.	2.0	112
204	Sinonasal Malignancies of Anterior Skull Base. <i>Otolaryngologic Clinics of North America</i> , 2016, 49, 183-200.	0.5	96
205	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 131-142.	2.0	82
206	Interim results from a phase II study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6029-6029.	0.8	1
207	Activity of afatinib administered in a window pre-operative study in squamous cell carcinoma of the head and neck (SCCHN) : EORTC-90111.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6049-6049.	0.8	4
208	Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 74362-74379.	0.8	149
209	Individual patient data meta-analysis of the IMPACT of treatment site on the outcome of head and neck cancer patients treated within 6 randomized trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6022-6022.	0.8	0
210	Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2015, 44, 734-745.	1.4	8
211	Nausea and Vomiting during the First 3 Intercycle Periods in Chemo-naive Cancer Patients Receiving Moderately/Highly Emetogenic Therapy. <i>Tumori</i> , 2015, 101, 692-696.	0.6	4
212	Gastrointestinal toxicities from targeted therapies. <i>Current Opinion in Supportive and Palliative Care</i> , 2015, 9, 163-167.	0.5	7
213	Hope in Cancer Patients: The Relational Domain as a Crucial Factor. <i>Tumori</i> , 2015, 101, 447-454.	0.6	25
214	Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 191-213.	2.0	33
215	NICSO: Network Italiano Cure di Supporto in Oncologia â€“ Italian Network for Supportive Care in Oncology. <i>Supportive Care in Cancer</i> , 2015, 23, 11-12.	1.0	6
216	Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. <i>Cancer Research</i> , 2015, 75, 1205-1215.	0.4	78

#	ARTICLE	IF	CITATIONS
217	Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 167-182.	2.0	46
218	Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 372-384.	2.0	95
219	Italian version of the M.D. Anderson Symptom Inventory's Head and Neck Module: linguistic validation. <i>Supportive Care in Cancer</i> , 2015, 23, 3465-3472.	1.0	7
220	Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2015, 51, 2596-2603.	1.3	61
221	Comment on "Impact of intra-arterial chemotherapy including internal carotid artery for advanced paranasal sinus cancers involving the skull base". <i>British Journal of Cancer</i> , 2015, 113, 1638-1639.	2.9	0
222	The role of systemic therapy in the management of sinonasal cancer: A critical review. <i>Cancer Treatment Reviews</i> , 2015, 41, 836-843.	3.4	99
223	Smoothed (SMO) receptor mutations dictate resistance to Avisa modegib in basal cell carcinoma. <i>Molecular Oncology</i> , 2015, 9, 389-397.	2.1	131
224	Prevention of head and neck squamous cell carcinoma: Removing the "chemo" from "chemoprevention". <i>Oral Oncology</i> , 2015, 51, 112-118.	0.8	32
225	Differential impact of cisplatin dose intensity on human papillomavirus (HPV)-related (+) and HPV-unrelated (â) locoregionally advanced head and neck squamous cell carcinoma (LAHNSCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 6020-6020.	0.8	7
226	Treatment-associated mortality in head and neck cancer receiving chemotherapy and radiation: Meta-analysis of published trials.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6062-6062.	0.8	1
227	Health and economic outcomes of two different follow up strategies in effectively cured advanced head and neck cancer patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS6625-TPS6625.	0.8	1
228	Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data. <i>Oncotarget</i> , 2015, 6, 9627-9642.	0.8	103
229	Detecting characteristics of nodal invasion in advanced squamocellular oral cavity cancer through a gene expression profile on primary tumor.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17069-e17069.	0.8	0
230	Upregulation of RAS pathway to predict the risk of distant metastases in HPV + oropharynx cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17073-e17073.	0.8	0
231	Circulating pretreatment Epstein Barr Virus DNA quantification as a prognostic factor in nasopharyngeal cancer patients in a non endemic area.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17054-e17054.	0.8	0
232	Meta-analysis: Risk of congestive heart failure (CHF) in selected targeted agents.. <i>Journal of Clinical Oncology</i> , 2015, 33, 64-64.	0.8	1
233	Pain related to cancer treatments and diagnostic procedures: a no man's land?. <i>Annals of Oncology</i> , 2014, 25, 1097-1106.	0.6	28
234	Postoperative radiotherapy with volumetric modulated arc therapy of lacrimal gland carcinoma: two case reports and literature review. <i>Future Oncology</i> , 2014, 10, 2111-2120.	1.1	3

#	ARTICLE	IF	CITATIONS
235	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i> , 2014, 120, 1453-1461.	2.0	838
236	Radiotherapy for unresectable sinonasal cancers: Dosimetric comparison of intensity modulated radiation therapy with coplanar and non-coplanar volumetric modulated arc therapy. <i>Radiotherapy and Oncology</i> , 2014, 113, 260-266.	0.3	26
237	Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy. <i>Cancer Biology and Therapy</i> , 2014, 15, 678-682.	1.5	24
238	Prevention and treatment of oral mucositis in patients with head and neck cancer treated with (chemo) radiation: report of an Italian survey. <i>Supportive Care in Cancer</i> , 2014, 22, 1889-96.	1.0	23
239	Comprehensive gene expression meta-analysis of head and neck squamous cell carcinoma microarray data defines a robust survival predictor. <i>Annals of Oncology</i> , 2014, 25, 1628-1635.	0.6	45
240	Rapid-Onset Opioids for the Treatment of Breakthrough Cancer Pain: Two Cases of Drug Abuse: Table 1. <i>Pain Medicine</i> , 2014, 15, 758-761.	0.9	9
241	Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. <i>Annals of Oncology</i> , 2014, 25, 462-466.	0.6	83
242	Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer. <i>Oral Oncology</i> , 2014, 50, 884-887.	0.8	20
243	Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis. <i>Annals of Oncology</i> , 2014, 25, 694-699.	0.6	33
244	Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer. <i>Head and Neck</i> , 2013, 35, 1471-1474.	0.9	18
245	Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. <i>Supportive Care in Cancer</i> , 2013, 21, 3191-3207.	1.0	137
246	Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. <i>Supportive Care in Cancer</i> , 2013, 21, 3243-3254.	1.0	46
247	Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma. <i>Oral Oncology</i> , 2013, 49, 413-419.	0.8	39
248	Comments on "Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: Patterns of failure" by Chan and Coll. <i>Oral Oncology</i> , 2013, 49, e38.	0.8	1
249	Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma. <i>Future Oncology</i> , 2013, 9, 103-114.	1.1	28
250	Emerging tyrosine kinase inhibitors for head and neck cancer. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 445-459.	1.0	7
251	Abstract PR05: Resistance to Hedgehog inhibitor through Smoothed receptor mutation in basal cell carcinoma.., 2013, , .		1
252	Identification of a gene expression profile associated with progression-free survival (PFS) in relapsed or metastatic (RM) head and neck squamous cell cancer (HNSCC) patients (pts) treated with first-line cetuximab and platinum therapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, 6027-6027.	0.8	2

#	ARTICLE	IF	CITATIONS
253	T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. <i>Annals of Oncology</i> , 2012, 23, 435-441.	0.6	55
254	How Many Therapeutic Options Are There for Recurrent or Metastatic Salivary Duct Carcinoma?. <i>Journal of Clinical Oncology</i> , 2012, 30, 672-672.	0.8	4
255	Palifermin in Prevention of Head and Neck Cancer Radiation-Induced Mucositis: Not Yet a Definitive Word on Safety and Efficacy Profile. <i>Journal of Clinical Oncology</i> , 2012, 30, 564-565.	0.8	18
256	Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. <i>Annals of Oncology</i> , 2012, 23, 1832-1837.	0.6	97
257	Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, e226-e228.	0.6	7
258	Isolating p16-positive/HPV-negative Oropharyngeal Cancer. <i>American Journal of Surgical Pathology</i> , 2011, 35, 774-777.	2.1	65
259	Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients. <i>Annals of Oncology</i> , 2011, 22, 1886-1893.	0.6	24
260	Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer. <i>Annals of Oncology</i> , 2011, 22, 2495-2500.	0.6	31
261	Carcinoma del rinofaringe. , 2011, , 293-307.		0
262	Carcinomi dei seni paranasali e delle fosse nasali. , 2011, , 371-390.		0
263	Comment on "Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): A matched pair analysis" by Rades et coll.. <i>Oral Oncology</i> , 2010, 46, 888.	0.8	0
264	TP53 Mutations and Pathologic Complete Response to Neoadjuvant Cisplatin and Fluorouracil Chemotherapy in Resected Oral Cavity Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 761-766.	0.8	104
265	Multikinase inhibitors in thyroid cancer. <i>European Journal of Cancer</i> , 2010, 46, 1012-1018.	1.3	14
266	Fragile Histidine Triad Gene Inactivation in Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 396-401.	2.5	63
267	Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. <i>Oral Oncology</i> , 2009, 45, 574-578.	0.8	184
268	Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). <i>Oral Oncology</i> , 2009, 45, 986-990.	0.8	144
269	Further Improvement in Outcomes of Nasopharyngeal Carcinoma With Optimized Radiotherapy and Induction Plus Concomitant Chemotherapy: An Update of the Milan Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 774-780.	0.4	35
270	Oropharyngeal Squamous Cell Carcinoma Treated With Radiotherapy or Radiochemotherapy: Prognostic Role of TP53 and HPV Status. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1053-1059.	0.4	39

#	ARTICLE	IF	CITATIONS
271	Folate in Head and Neck Squamous Cell Cancer Chemoprevention: Purposely Left Out?. Journal of Clinical Oncology, 2008, 26, 3463-3463.	0.8	2
272	Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options. Annals of Oncology, 2008, 19, vii200-vii203.	0.6	18
273	TP53 Mutations in Head and Neck Cancer. New England Journal of Medicine, 2008, 358, 1194-1195.	13.9	1
274	Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. Annals of Oncology, 2007, 18, 601-602.	0.6	26
275	Biological agents in head and neck cancer. Expert Review of Anticancer Therapy, 2007, 7, 1643-1650.	1.1	4
276	Molecular and Cytogenetic Subgroups of Oropharyngeal Squamous Cell Carcinoma. Clinical Cancer Research, 2006, 12, 6643-6651.	3.2	159
277	A multidisciplinary approach to squamous cell carcinomas of the head and neck: what is new?. Current Opinion in Oncology, 2006, 18, 253-257.	1.1	24
278	Advances in the changing patterns of aetiology of head and neck cancers. Current Opinion in Otolaryngology and Head and Neck Surgery, 2006, 14, 95-99.	0.8	7
279	Biological agents in head and neck cancer. Annals of Oncology, 2006, 17, x45-x48.	0.6	3
280	High-Risk Human Papillomavirus Affects Prognosis in Patients With Surgically Treated Oropharyngeal Squamous Cell Carcinoma. Journal of Clinical Oncology, 2006, 24, 5630-5636.	0.8	605
281	Herceptin® plus chemotherapy in relapsed and/or metastatic salivary gland cancer. Oral Oncology, 2005, 41, 97-98.	0.8	23
282	Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland. Oral Oncology, 2005, 41, 890-894.	0.8	58
283	Is Restoring Platinum Sensitivity the Best Goal for Cetuximab in Recurrent/Metastatic Nasopharyngeal Cancer?. Journal of Clinical Oncology, 2005, 23, 7757-7758.	0.8	7
284	Is PSA useful in the diagnosis and monitoring of parotid adenocarcinomas?. Oral Oncology, 2005, 41, 219-221.	0.7	0
285	Cisplatin and Fluorouracil Concurrent to Radiotherapy in Nasopharyngeal Cancer: Is the Schedule Compatible?. Journal of Clinical Oncology, 2004, 22, 377-377.	0.8	1
286	Prediction of TP53 Status for Primary Cisplatin, Fluorouracil, and Leucovorin Chemotherapy in Ethmoid Sinus Intestinal-Type Adenocarcinoma. Journal of Clinical Oncology, 2004, 22, 4901-4906.	0.8	99
287	Head and neck tumors other than squamous cell carcinoma. Current Opinion in Oncology, 2004, 16, 236-241.	1.1	18
288	Timing of Chemoradiotherapy and Patient Selection for Locally Advanced Nasopharyngeal Carcinoma. Clinical Oncology, 2003, 15, 451-460.	0.6	13

#	ARTICLE	IF	CITATIONS
289	A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. <i>Annals of Oncology</i> , 2003, 14, 1327-1328.	0.6	55
290	Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice. <i>Frontiers in Pain Research</i> , 0, 3, .	0.9	4